Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0010200 (
cough
)
23,843
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cough
is the most common reason to visit a primary care physician, yet it remains an unmet medical need. Fatty acid amide hydrolase (FAAH) is an enzyme that breaks down endocannabinoids, and inhibition of FAAH produces analgesic and anti-inflammatory effects. Cannabinoids inhibit vagal sensory nerve activation and the
cough
reflex, so it was hypothesised that FAAH inhibition would produce antitussive activity
via
elevation of endocannabinoids.Primary vagal ganglia neurons, tissue bioassay,
in vivo
electrophysiology and a conscious guinea pig
cough
model were utilised to investigate a role for fatty acid amides in modulating sensory nerve activation in vagal afferents.FAAH inhibition produced antitussive activity in guinea pigs with concomitant plasma elevation of the fatty acid amides
N
-arachidonoylethanolamide (anandamide), palmitoylethanolamide,
N
-oleoylethanolamide and linoleoylethanolamide.
Palmitoylethanolamide
inhibited tussive stimulus-induced activation of guinea pig airway innervating vagal ganglia neurons, depolarisation of guinea pig and human vagus, and firing of C-fibre afferents. These effects were mediated
via
a cannabinoid CB
2
/G
i/o
-coupled pathway and activation of protein phosphatase 2A, resulting in increased calcium sensitivity of calcium-activated potassium channels.These findings identify FAAH inhibition as a target for the development of novel, antitussive agents without the undesirable side-effects of direct cannabinoid receptor agonists.
...
PMID:Targeting fatty acid amide hydrolase as a therapeutic strategy for antitussive therapy. 2893 72